Cargando…
High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients
BACKGROUND: Viral shedding and neutralizing antibody (NAb) dynamics among patients hospitalized with severe coronavirus disease 2019 (COVID-19) and immune correlates of protection have been key questions throughout the pandemic. We investigated the duration of reverse transcriptase-polymerase chain...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875770/ https://www.ncbi.nlm.nih.gov/pubmed/36698135 http://dx.doi.org/10.1186/s12985-023-01974-8 |
_version_ | 1784878027484692480 |
---|---|
author | Sejdic, Adin Frische, Anders Jørgensen, Charlotte Sværke Rasmussen, Lasse Dam Trebbien, Ramona Dungu, Arnold Holler, Jon G. Ostrowski, Sisse Rye Eriksson, Robert Søborg, Christian Nielsen, Thyge L. Fischer, Thea K. Lindegaard, Birgitte Franck, Kristina Træholt Harboe, Zitta Barrella |
author_facet | Sejdic, Adin Frische, Anders Jørgensen, Charlotte Sværke Rasmussen, Lasse Dam Trebbien, Ramona Dungu, Arnold Holler, Jon G. Ostrowski, Sisse Rye Eriksson, Robert Søborg, Christian Nielsen, Thyge L. Fischer, Thea K. Lindegaard, Birgitte Franck, Kristina Træholt Harboe, Zitta Barrella |
author_sort | Sejdic, Adin |
collection | PubMed |
description | BACKGROUND: Viral shedding and neutralizing antibody (NAb) dynamics among patients hospitalized with severe coronavirus disease 2019 (COVID-19) and immune correlates of protection have been key questions throughout the pandemic. We investigated the duration of reverse transcriptase-polymerase chain reaction (RT-PCR) positivity, infectious viral shedding and NAb titers as well as the association between NAb titers and disease severity in hospitalized COVID-19 patients in Denmark 2020–2021. MATERIALS AND METHODS: Prospective single-center observational cohort study of 47 hospitalized COVID-19 patients. Oropharyngeal swabs were collected at eight time points during the initial 30 days of inclusion. Serum samples were collected after a median time of 7 (IQR 5 – 10), 37 (IQR 35 – 38), 97 (IQR 95 – 100), and 187 (IQR 185 – 190) days after symptom onset. NAb titers were determined by an in-house live virus microneutralization assay. Viral culturing was performed in Vero E6 cells. RESULTS: Patients with high disease severity had higher mean log(2) NAb titers at day 37 (1.58, 95% CI [0.34 –2.81]), 97 (2.07, 95% CI [0.53–3.62]) and 187 (2.49, 95% CI [0.20– 4.78]) after symptom onset, compared to patients with low disease severity. Peak viral load (0.072, 95% CI [− 0.627 – 0.728]), expressed as log(10) SARS-CoV-2 copies/ml, was not associated with disease severity. Virus cultivation attempts were unsuccessful in almost all (60/61) oropharyngeal samples collected shortly after hospital admission. CONCLUSIONS: We document an association between high disease severity and high mean NAb titers at days 37, 97 and 187 after symptom onset. However, peak viral load during admission was not associated with disease severity. Trial registration. The study is registered at https://clinicaltrials.gov/ (NCT05274373). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-01974-8. |
format | Online Article Text |
id | pubmed-9875770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98757702023-01-25 High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients Sejdic, Adin Frische, Anders Jørgensen, Charlotte Sværke Rasmussen, Lasse Dam Trebbien, Ramona Dungu, Arnold Holler, Jon G. Ostrowski, Sisse Rye Eriksson, Robert Søborg, Christian Nielsen, Thyge L. Fischer, Thea K. Lindegaard, Birgitte Franck, Kristina Træholt Harboe, Zitta Barrella Virol J Research BACKGROUND: Viral shedding and neutralizing antibody (NAb) dynamics among patients hospitalized with severe coronavirus disease 2019 (COVID-19) and immune correlates of protection have been key questions throughout the pandemic. We investigated the duration of reverse transcriptase-polymerase chain reaction (RT-PCR) positivity, infectious viral shedding and NAb titers as well as the association between NAb titers and disease severity in hospitalized COVID-19 patients in Denmark 2020–2021. MATERIALS AND METHODS: Prospective single-center observational cohort study of 47 hospitalized COVID-19 patients. Oropharyngeal swabs were collected at eight time points during the initial 30 days of inclusion. Serum samples were collected after a median time of 7 (IQR 5 – 10), 37 (IQR 35 – 38), 97 (IQR 95 – 100), and 187 (IQR 185 – 190) days after symptom onset. NAb titers were determined by an in-house live virus microneutralization assay. Viral culturing was performed in Vero E6 cells. RESULTS: Patients with high disease severity had higher mean log(2) NAb titers at day 37 (1.58, 95% CI [0.34 –2.81]), 97 (2.07, 95% CI [0.53–3.62]) and 187 (2.49, 95% CI [0.20– 4.78]) after symptom onset, compared to patients with low disease severity. Peak viral load (0.072, 95% CI [− 0.627 – 0.728]), expressed as log(10) SARS-CoV-2 copies/ml, was not associated with disease severity. Virus cultivation attempts were unsuccessful in almost all (60/61) oropharyngeal samples collected shortly after hospital admission. CONCLUSIONS: We document an association between high disease severity and high mean NAb titers at days 37, 97 and 187 after symptom onset. However, peak viral load during admission was not associated with disease severity. Trial registration. The study is registered at https://clinicaltrials.gov/ (NCT05274373). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-01974-8. BioMed Central 2023-01-25 /pmc/articles/PMC9875770/ /pubmed/36698135 http://dx.doi.org/10.1186/s12985-023-01974-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Sejdic, Adin Frische, Anders Jørgensen, Charlotte Sværke Rasmussen, Lasse Dam Trebbien, Ramona Dungu, Arnold Holler, Jon G. Ostrowski, Sisse Rye Eriksson, Robert Søborg, Christian Nielsen, Thyge L. Fischer, Thea K. Lindegaard, Birgitte Franck, Kristina Træholt Harboe, Zitta Barrella High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients |
title | High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients |
title_full | High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients |
title_fullStr | High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients |
title_full_unstemmed | High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients |
title_short | High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients |
title_sort | high titers of neutralizing sars-cov-2 antibodies six months after symptom onset are associated with increased severity in covid-19 hospitalized patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875770/ https://www.ncbi.nlm.nih.gov/pubmed/36698135 http://dx.doi.org/10.1186/s12985-023-01974-8 |
work_keys_str_mv | AT sejdicadin hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT frischeanders hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT jørgensencharlottesværke hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT rasmussenlassedam hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT trebbienramona hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT dunguarnold hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT hollerjong hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT ostrowskisisserye hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT erikssonrobert hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT søborgchristian hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT nielsenthygel hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT fischertheak hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT lindegaardbirgitte hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT franckkristinatræholt hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients AT harboezittabarrella hightitersofneutralizingsarscov2antibodiessixmonthsaftersymptomonsetareassociatedwithincreasedseverityincovid19hospitalizedpatients |